Skip to main content
Erschienen in: Current Treatment Options in Neurology 11/2016

01.11.2016 | Sleep Disorders (A Iranzo, Section Editor)

Treatment of REM Sleep Behavior Disorder

verfasst von: Youngsin Jung, MD, PhD, Erik K. St. Louis, MD

Erschienen in: Current Treatment Options in Neurology | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Opinion statement

REM sleep behavior disorder (RBD) is a common parasomnia disorder affecting between 1 and 7 % of community-dwelling adults, most frequently older adults. RBD is characterized by nocturnal complex motor behavior and polysomnographic REM sleep without atonia. RBD is strongly associated with synucleinopathy neurodegeneration. The approach to RBD management is currently twofold: symptomatic treatment to prevent injury and prognostic counseling and longitudinal follow-up surveillance for phenoconversion toward overt neurodegenerative disorders. The focus of this review is symptomatic treatment for injury prevention. Injury occurs in up to 55 % of patients prior to treatment, even when most behaviors seem to be infrequent or minor, so patients with RBD should be treated promptly following diagnosis to prevent injury risk. A sound evidence basis for symptomatic treatment of RBD remains lacking, and randomized controlled treatment trials are needed. Traditional therapeutic mainstays with relatively robust retrospective case series level evidence include melatonin and clonazepam, which appear to be equally effective, although melatonin is more tolerable. Melatonin also has one small randomized controlled crossover trial supporting its use for RBD treatment. Melatonin dosed 3–12 mg at bedtime should be considered as the first-line therapy, followed by clonazepam 0.25–2.0 mg at bedtime if initial melatonin is judged ineffective or intolerable. However, neither agent is likely to completely stop dream enactment behaviors, so choosing a moderate target dosage of melatonin 6 mg or clonazepam 0.5 mg, or the highest tolerable dosage that reduces attack frequency and avoids adverse effects from overtreatment, is currently the most reasonable strategy. Alternative second- and third-line therapies with anecdotal efficacy include temazepam, lorazepam, zolpidem, zopiclone, pramipexole, donepezil, ramelteon, agomelatine, cannabinoids, and sodium oxybate. A novel non-pharmacological approach is a bed alarm system, although this may be most useful in patients who also report sleep walking or a history of leaving their bed during dream enactment episodes. The benefit of hypnosis, especially in those with psychiatric RBD, also requires further study. RBD is an attractive target for future neuroprotective treatment trials to prevent evolution of overt parkinsonism or memory decline, but currently, there are no known effective treatments and future trials will be necessary to determine if RBD is an actionable time point in the evolution of overt synucleinopathy.
Literatur
1.
Zurück zum Zitat Schenck CH et al. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep. 1986;9(2):293–308.PubMed Schenck CH et al. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep. 1986;9(2):293–308.PubMed
2.•
Zurück zum Zitat Schenck CH, Mahowald MW. REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP. Sleep. 2002;25(2):120–38. This landmark article describes clinical and therapeutic approaches in a large series of REM sleep behavior disorder by the sleep neurology pioneers, Schenck and Mahowald, who discovered and initially described the condition in humans at the Minnesota Regional Sleep Disorders Center based at Hennepin County Medical Center Sleep in Minneapolis.PubMed Schenck CH, Mahowald MW. REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP. Sleep. 2002;25(2):120–38. This landmark article describes clinical and therapeutic approaches in a large series of REM sleep behavior disorder by the sleep neurology pioneers, Schenck and Mahowald, who discovered and initially described the condition in humans at the Minnesota Regional Sleep Disorders Center based at Hennepin County Medical Center Sleep in Minneapolis.PubMed
3.
Zurück zum Zitat International classification of sleep disorders. 3rd ed. Westchester, IL: American Academy of Sleep Medicine 2014. International classification of sleep disorders. 3rd ed. Westchester, IL: American Academy of Sleep Medicine 2014.
4.•
Zurück zum Zitat Boeve BF. REM sleep behavior disorder: updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci. 2010;1184:15–54. This encyclopedic review article comprehensively reviews clinical, pathophysiologic, pathologic, imaging, and treatment aspects of REM sleep behavior disorder, including alternative approaches to treatment in refractory cases such as the use of sodium oxybate.PubMedPubMedCentralCrossRef Boeve BF. REM sleep behavior disorder: updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci. 2010;1184:15–54. This encyclopedic review article comprehensively reviews clinical, pathophysiologic, pathologic, imaging, and treatment aspects of REM sleep behavior disorder, including alternative approaches to treatment in refractory cases such as the use of sodium oxybate.PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Chiu HF et al. Sleep-related injury in the elderly—an epidemiological study in Hong Kong. Sleep. 2000;23(4):513–7.PubMed Chiu HF et al. Sleep-related injury in the elderly—an epidemiological study in Hong Kong. Sleep. 2000;23(4):513–7.PubMed
7.
Zurück zum Zitat Boeve BF et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med. 2011;12(5):445–53.PubMedPubMedCentralCrossRef Boeve BF et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med. 2011;12(5):445–53.PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Boot BP et al. Probable rapid eye movement sleep behavior disorder increases risk for mild cognitive impairment and Parkinson disease: a population-based study. Ann Neurol. 2012;71(1):49–56.PubMedPubMedCentralCrossRef Boot BP et al. Probable rapid eye movement sleep behavior disorder increases risk for mild cognitive impairment and Parkinson disease: a population-based study. Ann Neurol. 2012;71(1):49–56.PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Boeve BF et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med. 2013;14(8):754–62.PubMedPubMedCentralCrossRef Boeve BF et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med. 2013;14(8):754–62.PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Iranzo A et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol. 2013;12(5):443–53.PubMedCrossRef Iranzo A et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol. 2013;12(5):443–53.PubMedCrossRef
11.
Zurück zum Zitat Schenck CH et al. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med. 2013;14(8):744–8.PubMedCrossRef Schenck CH et al. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med. 2013;14(8):744–8.PubMedCrossRef
12.
13.
Zurück zum Zitat Postuma RB et al. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology. 2009;72(15):1296–300.PubMedPubMedCentralCrossRef Postuma RB et al. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology. 2009;72(15):1296–300.PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Iranzo A et al. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]. Lancet Neurol. 2010;9(11):1070–7.PubMedCrossRef Iranzo A et al. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]. Lancet Neurol. 2010;9(11):1070–7.PubMedCrossRef
15.•
Zurück zum Zitat Schenck CH et al. Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy—a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. Sleep Med. 2013;14(8):795–806. This consensus position paper of the International RBD Study Group proposes future approaches to symptomatic and neuroprotective clinical trials for REM sleep behavior disorder.PubMedCrossRef Schenck CH et al. Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy—a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. Sleep Med. 2013;14(8):795–806. This consensus position paper of the International RBD Study Group proposes future approaches to symptomatic and neuroprotective clinical trials for REM sleep behavior disorder.PubMedCrossRef
16.
Zurück zum Zitat Hancock KL et al. Quantitative analyses of REM sleep without atonia in children and adolescents with REM sleep behavior disorder. Minn Med. 2014;97(5):43.PubMed Hancock KL et al. Quantitative analyses of REM sleep without atonia in children and adolescents with REM sleep behavior disorder. Minn Med. 2014;97(5):43.PubMed
17.
Zurück zum Zitat Lloyd R et al. Characteristics of REM sleep behavior disorder in childhood. J Clin Sleep Med. 2012;8(2):127–31.PubMedPubMedCentral Lloyd R et al. Characteristics of REM sleep behavior disorder in childhood. J Clin Sleep Med. 2012;8(2):127–31.PubMedPubMedCentral
18.
Zurück zum Zitat Dauvilliers Y et al. Rapid eye movement sleep behavior disorder and rapid eye movement sleep without atonia in narcolepsy. Sleep Med. 2013;14(8):775–81.PubMedCrossRef Dauvilliers Y et al. Rapid eye movement sleep behavior disorder and rapid eye movement sleep without atonia in narcolepsy. Sleep Med. 2013;14(8):775–81.PubMedCrossRef
20.
Zurück zum Zitat McCarter SJ et al. Neuroimaging-evident lesional pathology associated with REM sleep behavior disorder. Sleep Med. 2015;16(12):1502–10.PubMedCrossRef McCarter SJ et al. Neuroimaging-evident lesional pathology associated with REM sleep behavior disorder. Sleep Med. 2015;16(12):1502–10.PubMedCrossRef
21.
Zurück zum Zitat Iranzo A et al. Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis. Ann Neurol. 2006;59(1):178–81.PubMedCrossRef Iranzo A et al. Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis. Ann Neurol. 2006;59(1):178–81.PubMedCrossRef
22.
Zurück zum Zitat Cornelius JR et al. Sleep manifestations of voltage-gated potassium channel complex autoimmunity. Arch Neurol. 2011;68(6):733–8.PubMedCrossRef Cornelius JR et al. Sleep manifestations of voltage-gated potassium channel complex autoimmunity. Arch Neurol. 2011;68(6):733–8.PubMedCrossRef
23.
Zurück zum Zitat Lee K, et al. The Prevalence and Characteristics of REM Sleep without Atonia (RSWA) in Patients Taking Antidepressants. J Clin Sleep Med. 2015. Lee K, et al. The Prevalence and Characteristics of REM Sleep without Atonia (RSWA) in Patients Taking Antidepressants. J Clin Sleep Med. 2015.
24.
Zurück zum Zitat Postuma RB et al. Antidepressants and REM sleep behavior disorder: isolated side effect or neurodegenerative signal? Sleep. 2013;36(11):1579–85.PubMedPubMedCentral Postuma RB et al. Antidepressants and REM sleep behavior disorder: isolated side effect or neurodegenerative signal? Sleep. 2013;36(11):1579–85.PubMedPubMedCentral
25.
Zurück zum Zitat McCarter SJ et al. Antidepressants Increase REM Sleep Muscle Tone in Patients with and without REM Sleep Behavior Disorder. Sleep. 2015;38(6):907–17.PubMedPubMedCentral McCarter SJ et al. Antidepressants Increase REM Sleep Muscle Tone in Patients with and without REM Sleep Behavior Disorder. Sleep. 2015;38(6):907–17.PubMedPubMedCentral
26.
Zurück zum Zitat Feinstein M SR, Sandness DJ, Timm PC, Lipford M, Tippmann-Peikert M, Junna M, Silber MH, Boeve BF, St. Louis EK. Counseling of the patient with idiopathic REM sleep behavior disorder and incidental polysomnographic REM sleep without atonia: a retrospective analysis. Sleep. 2016;39(Suppl (abstract)):A239. Feinstein M SR, Sandness DJ, Timm PC, Lipford M, Tippmann-Peikert M, Junna M, Silber MH, Boeve BF, St. Louis EK. Counseling of the patient with idiopathic REM sleep behavior disorder and incidental polysomnographic REM sleep without atonia: a retrospective analysis. Sleep. 2016;39(Suppl (abstract)):A239.
27.
Zurück zum Zitat Arnaldi D AE, St. Louis EK, Postuma RB, Arnulf I. Idiopathic REM sleep behavior disorder and neurodegenerative risk: to tell or not to tell the patient, and how to minimize the risk? (Unpublished observations, manuscript). Arnaldi D AE, St. Louis EK, Postuma RB, Arnulf I. Idiopathic REM sleep behavior disorder and neurodegenerative risk: to tell or not to tell the patient, and how to minimize the risk? (Unpublished observations, manuscript).
28.
Zurück zum Zitat Boeve BF et al. REM sleep behavior disorder and degenerative dementia: an association likely reflecting Lewy body disease. Neurology. 1998;51(2):363–70.PubMedCrossRef Boeve BF et al. REM sleep behavior disorder and degenerative dementia: an association likely reflecting Lewy body disease. Neurology. 1998;51(2):363–70.PubMedCrossRef
29.
Zurück zum Zitat Comella CL et al. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson’s disease. Neurology. 1998;51(2):526–9.PubMedCrossRef Comella CL et al. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson’s disease. Neurology. 1998;51(2):526–9.PubMedCrossRef
30.
Zurück zum Zitat Olson EJ et al. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain. 2000;123(Pt 2):331–9.PubMedCrossRef Olson EJ et al. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain. 2000;123(Pt 2):331–9.PubMedCrossRef
31.•
Zurück zum Zitat McCarter SJ et al. Factors associated with injury in REM sleep behavior disorder. Sleep Med. 2014;15(11):1332–8. This paper reviewed the frequency of injury in untreated REM sleep behavior disorder, finding that 55% of idiopathic RBD patients reported injury prior to treatment, 11.3% with serious injuries such as subdural hematomas. While not discussing treatment per se, the alarming frequency of injury suggest that treatment to prevent injury should be a major priority in the care of RBD patients.PubMedPubMedCentralCrossRef McCarter SJ et al. Factors associated with injury in REM sleep behavior disorder. Sleep Med. 2014;15(11):1332–8. This paper reviewed the frequency of injury in untreated REM sleep behavior disorder, finding that 55% of idiopathic RBD patients reported injury prior to treatment, 11.3% with serious injuries such as subdural hematomas. While not discussing treatment per se, the alarming frequency of injury suggest that treatment to prevent injury should be a major priority in the care of RBD patients.PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Chokroverty S. Editorial: “Injurious RBD and DEB frequency: are they related?”. Sleep Med. 2014;15(11):1287.PubMedCrossRef Chokroverty S. Editorial: “Injurious RBD and DEB frequency: are they related?”. Sleep Med. 2014;15(11):1287.PubMedCrossRef
33.
Zurück zum Zitat Schenck CH et al. Symposium: Normal and abnormal REM sleep regulation: REM sleep behaviour disorder: an update on a series of 96 patients and a review of the world literature. J Sleep Res. 1993;2(4):224–31.PubMedCrossRef Schenck CH et al. Symposium: Normal and abnormal REM sleep regulation: REM sleep behaviour disorder: an update on a series of 96 patients and a review of the world literature. J Sleep Res. 1993;2(4):224–31.PubMedCrossRef
34.
Zurück zum Zitat McCarter SJ et al. REM sleep behavior disorder and REM sleep without atonia as an early manifestation of degenerative neurological disease. Curr Neurol Neurosci Rep. 2012;12(2):182–92.PubMedPubMedCentralCrossRef McCarter SJ et al. REM sleep behavior disorder and REM sleep without atonia as an early manifestation of degenerative neurological disease. Curr Neurol Neurosci Rep. 2012;12(2):182–92.PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Boeve BF et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain. 2007;130(Pt 11):2770–88.PubMedCrossRef Boeve BF et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain. 2007;130(Pt 11):2770–88.PubMedCrossRef
36.•
Zurück zum Zitat Anderson KN, Shneerson JM. Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam. J Clin Sleep Med. 2009;5(3):235–9. This article assessed alternative treatments to clonazepam used in open clinical experience in REM sleep behavior disorder management, especially finding zopiclone as a suitable alternative in some patients.PubMedPubMedCentral Anderson KN, Shneerson JM. Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam. J Clin Sleep Med. 2009;5(3):235–9. This article assessed alternative treatments to clonazepam used in open clinical experience in REM sleep behavior disorder management, especially finding zopiclone as a suitable alternative in some patients.PubMedPubMedCentral
37.
Zurück zum Zitat Brooks PL, Peever JH. Impaired GABA and glycine transmission triggers cardinal features of rapid eye movement sleep behavior disorder in mice. J Neurosci. 2011;31(19):7111–21.PubMedCrossRef Brooks PL, Peever JH. Impaired GABA and glycine transmission triggers cardinal features of rapid eye movement sleep behavior disorder in mice. J Neurosci. 2011;31(19):7111–21.PubMedCrossRef
38.
Zurück zum Zitat Lapierre O, Montplaisir J. Polysomnographic features of REM sleep behavior disorder: development of a scoring method. Neurology. 1992;42(7):1371–4.PubMedCrossRef Lapierre O, Montplaisir J. Polysomnographic features of REM sleep behavior disorder: development of a scoring method. Neurology. 1992;42(7):1371–4.PubMedCrossRef
39.
Zurück zum Zitat Ferri R et al. An observational clinical and video-polysomnographic study of the effects of clonazepam in REM sleep behavior disorder. Sleep Med. 2013;14(1):24–9.PubMedCrossRef Ferri R et al. An observational clinical and video-polysomnographic study of the effects of clonazepam in REM sleep behavior disorder. Sleep Med. 2013;14(1):24–9.PubMedCrossRef
40.••
Zurück zum Zitat Li SX et al. A prospective, naturalistic follow-up study of treatment outcomes with clonazepam in rapid eye movement sleep behavior disorder. Sleep Med. 2016;21:114–20. This excellent new open study of clonazepam in 39 RBD patients found that an effective Treatment response, as defined by a complete elimination of sleep-related injuries and potentially injurious behaviors to self and/or to bed partner, was reported in 66.7% of the patients. Interestingly, there was no apparent effect on polysomnographic REM atonia, and decreased nightmarish dream content seemed most associated with efficacy.Patients with earlier onset RBD symptoms or history of co-morbid sleep apnea showed less beneficial treatment responses to clonazepam.PubMedCrossRef Li SX et al. A prospective, naturalistic follow-up study of treatment outcomes with clonazepam in rapid eye movement sleep behavior disorder. Sleep Med. 2016;21:114–20. This excellent new open study of clonazepam in 39 RBD patients found that an effective Treatment response, as defined by a complete elimination of sleep-related injuries and potentially injurious behaviors to self and/or to bed partner, was reported in 66.7% of the patients. Interestingly, there was no apparent effect on polysomnographic REM atonia, and decreased nightmarish dream content seemed most associated with efficacy.Patients with earlier onset RBD symptoms or history of co-morbid sleep apnea showed less beneficial treatment responses to clonazepam.PubMedCrossRef
41.
Zurück zum Zitat Bonakis A et al. REM sleep behaviour disorder (RBD) and its associations in young patients. Sleep Med. 2009;10(6):641–5.PubMedCrossRef Bonakis A et al. REM sleep behaviour disorder (RBD) and its associations in young patients. Sleep Med. 2009;10(6):641–5.PubMedCrossRef
42.••
Zurück zum Zitat Schenck CH, Mahowald MW. Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. Am J Med. 1996;100(3):333–7. This large case series reported the efficacy and long term tolerability of clonazepam for treatment of injurious parasomnias including 52 patients with REM sleep behavior disorder, finding effective control in the majority of patients.PubMedCrossRef Schenck CH, Mahowald MW. Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. Am J Med. 1996;100(3):333–7. This large case series reported the efficacy and long term tolerability of clonazepam for treatment of injurious parasomnias including 52 patients with REM sleep behavior disorder, finding effective control in the majority of patients.PubMedCrossRef
43.••
Zurück zum Zitat McCarter SJ et al. Treatment outcomes in REM sleep behavior disorder. Sleep Med. 2013;14(3):237–42. This case series of 45 REM sleep behavior disorder patients remains the largest comparative study between melatonin and clonazepam to date, finding through survey based patient reported outcomes that both treatments were approximately equally effective at reducing RBD frequency and severity, while melatonin was better tolerated.PubMedPubMedCentralCrossRef McCarter SJ et al. Treatment outcomes in REM sleep behavior disorder. Sleep Med. 2013;14(3):237–42. This case series of 45 REM sleep behavior disorder patients remains the largest comparative study between melatonin and clonazepam to date, finding through survey based patient reported outcomes that both treatments were approximately equally effective at reducing RBD frequency and severity, while melatonin was better tolerated.PubMedPubMedCentralCrossRef
44.•
Zurück zum Zitat Aurora RN et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010;6(1):85–95. This article comprehensively assessed available literature through 2010 concerning REM sleep behavior disorder treatment, and as the present review, concentrated on clonazepam and melatonin but also examining then published alternative., and also provided evidence level ratings for various treatments, reporting Level A evidence for safety measures, Level B for clonazepam and melatonin, and Level C for other alternatives such as pramipexole, zopiclone, benzodiazepines other than clonazepam, Yi-Gan San, desipramine, clozapine, carbamazepine, and sodium oxybate.PubMedPubMedCentral Aurora RN et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010;6(1):85–95. This article comprehensively assessed available literature through 2010 concerning REM sleep behavior disorder treatment, and as the present review, concentrated on clonazepam and melatonin but also examining then published alternative., and also provided evidence level ratings for various treatments, reporting Level A evidence for safety measures, Level B for clonazepam and melatonin, and Level C for other alternatives such as pramipexole, zopiclone, benzodiazepines other than clonazepam, Yi-Gan San, desipramine, clozapine, carbamazepine, and sodium oxybate.PubMedPubMedCentral
45.••
Zurück zum Zitat Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res. 2010;19(4):591–6. This small randomized crossover trial showed efficacy of melatonin and its apparent biological impact on improving REM sleep atonia in 8 patients with REM sleep behavior disorder.PubMedCrossRef Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res. 2010;19(4):591–6. This small randomized crossover trial showed efficacy of melatonin and its apparent biological impact on improving REM sleep atonia in 8 patients with REM sleep behavior disorder.PubMedCrossRef
46.
Zurück zum Zitat Kunz D, Bes F. Melatonin as a therapy in REM sleep behavior disorder patients: an open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation. Mov Disord. 1999;14(3):507–11.PubMedCrossRef Kunz D, Bes F. Melatonin as a therapy in REM sleep behavior disorder patients: an open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation. Mov Disord. 1999;14(3):507–11.PubMedCrossRef
47.
Zurück zum Zitat Takeuchi N et al. Melatonin therapy for REM sleep behavior disorder. Psychiatry Clin Neurosci. 2001;55(3):267–9.PubMedCrossRef Takeuchi N et al. Melatonin therapy for REM sleep behavior disorder. Psychiatry Clin Neurosci. 2001;55(3):267–9.PubMedCrossRef
48.•
Zurück zum Zitat Boeve BF et al. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med. 2003;4(4):281–4. This case series showed practical clinical utility for melatonin therapy for REM sleep behavior disorder.PubMedCrossRef Boeve BF et al. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med. 2003;4(4):281–4. This case series showed practical clinical utility for melatonin therapy for REM sleep behavior disorder.PubMedCrossRef
49.
Zurück zum Zitat Attenburrow ME et al. Low dose melatonin improves sleep in healthy middle-aged subjects. Psychopharmacology (Berl). 1996;126(2):179–81.CrossRef Attenburrow ME et al. Low dose melatonin improves sleep in healthy middle-aged subjects. Psychopharmacology (Berl). 1996;126(2):179–81.CrossRef
50.
Zurück zum Zitat Zhdanova IV et al. Effects of low oral doses of melatonin, given 2–4 hours before habitual bedtime, on sleep in normal young humans. Sleep. 1996;19(5):423–31.PubMed Zhdanova IV et al. Effects of low oral doses of melatonin, given 2–4 hours before habitual bedtime, on sleep in normal young humans. Sleep. 1996;19(5):423–31.PubMed
51.
Zurück zum Zitat Kunz D et al. Melatonin in patients with reduced REM sleep duration: two randomized controlled trials. J Clin Endocrinol Metab. 2004;89(1):128–34.PubMedCrossRef Kunz D et al. Melatonin in patients with reduced REM sleep duration: two randomized controlled trials. J Clin Endocrinol Metab. 2004;89(1):128–34.PubMedCrossRef
52.
Zurück zum Zitat Nomura T et al. Use of ramelteon for the treatment of secondary REM sleep behavior disorder. Intern Med. 2013;52(18):2123–6.PubMedCrossRef Nomura T et al. Use of ramelteon for the treatment of secondary REM sleep behavior disorder. Intern Med. 2013;52(18):2123–6.PubMedCrossRef
53.
Zurück zum Zitat Esaki Y, et al. An Open-Labeled Trial of Ramelteon in Idiopathic Rapid Eye Movement Sleep Behavior Disorder. J Clin Sleep Med. 2016. Esaki Y, et al. An Open-Labeled Trial of Ramelteon in Idiopathic Rapid Eye Movement Sleep Behavior Disorder. J Clin Sleep Med. 2016.
54.
Zurück zum Zitat St. Louis EK, McCarter SJ, Boeve BF. Ramelteon for idiopathic REM sleep behavior disorder: implications for pathophysiology and future treatment trials. JCSM. 2016;12(5):643–5. St. Louis EK, McCarter SJ, Boeve BF. Ramelteon for idiopathic REM sleep behavior disorder: implications for pathophysiology and future treatment trials. JCSM. 2016;12(5):643–5.
55.
Zurück zum Zitat Bonakis A et al. Agomelatine may improve REM sleep behavior disorder symptoms. J Clin Psychopharmacol. 2012;32(5):732–4.PubMedCrossRef Bonakis A et al. Agomelatine may improve REM sleep behavior disorder symptoms. J Clin Psychopharmacol. 2012;32(5):732–4.PubMedCrossRef
56.
Zurück zum Zitat Zucconi M, et al. Agomelatine in idiopathic REM sleep behavior disorder. 37. 2014;Supplement:A212. Zucconi M, et al. Agomelatine in idiopathic REM sleep behavior disorder. 37. 2014;Supplement:A212.
57.
Zurück zum Zitat Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev. 2002;2:CD001520. Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev. 2002;2:CD001520.
59.
Zurück zum Zitat Verhave PS et al. REM sleep behavior disorder in the marmoset MPTP model of early Parkinson disease. Sleep. 2011;34(8):1119–25.PubMedPubMedCentral Verhave PS et al. REM sleep behavior disorder in the marmoset MPTP model of early Parkinson disease. Sleep. 2011;34(8):1119–25.PubMedPubMedCentral
60.
Zurück zum Zitat Fantini ML et al. The effects of pramipexole in REM sleep behavior disorder. Neurology. 2003;61(10):1418–20.PubMedCrossRef Fantini ML et al. The effects of pramipexole in REM sleep behavior disorder. Neurology. 2003;61(10):1418–20.PubMedCrossRef
61.
Zurück zum Zitat Schmidt MH et al. Use of pramipexole in REM sleep behavior disorder: results from a case series. Sleep Med. 2006;7(5):418–23.PubMedCrossRef Schmidt MH et al. Use of pramipexole in REM sleep behavior disorder: results from a case series. Sleep Med. 2006;7(5):418–23.PubMedCrossRef
62.
Zurück zum Zitat Sasai T et al. Factors associated with the effect of pramipexole on symptoms of idiopathic REM sleep behavior disorder. Parkinsonism Relat Disord. 2013;19(2):153–7.PubMedCrossRef Sasai T et al. Factors associated with the effect of pramipexole on symptoms of idiopathic REM sleep behavior disorder. Parkinsonism Relat Disord. 2013;19(2):153–7.PubMedCrossRef
63.
Zurück zum Zitat Kumru H et al. Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease. Sleep. 2008;31(10):1418–21.PubMedPubMedCentral Kumru H et al. Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease. Sleep. 2008;31(10):1418–21.PubMedPubMedCentral
64.
Zurück zum Zitat Shiromani PJ et al. Acetylcholine and the regulation of REM sleep: basic mechanisms and clinical implications for affective illness and narcolepsy. Annu Rev Pharmacol Toxicol. 1987;27:137–56.PubMedCrossRef Shiromani PJ et al. Acetylcholine and the regulation of REM sleep: basic mechanisms and clinical implications for affective illness and narcolepsy. Annu Rev Pharmacol Toxicol. 1987;27:137–56.PubMedCrossRef
65.
Zurück zum Zitat Jones BE. The organization of central cholinergic systems and their functional importance in sleep-waking states. Prog Brain Res. 1993;98:61–71.PubMedCrossRef Jones BE. The organization of central cholinergic systems and their functional importance in sleep-waking states. Prog Brain Res. 1993;98:61–71.PubMedCrossRef
66.
Zurück zum Zitat Holsboer-Trachsler E et al. Effects of the novel acetylcholinesterase inhibitor SDZ ENA 713 on sleep in man. Neuropsychopharmacology. 1993;8(1):87–92.PubMedCrossRef Holsboer-Trachsler E et al. Effects of the novel acetylcholinesterase inhibitor SDZ ENA 713 on sleep in man. Neuropsychopharmacology. 1993;8(1):87–92.PubMedCrossRef
67.
Zurück zum Zitat Ringman JM, Simmons JH. Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology. 2000;55(6):870–1.PubMedCrossRef Ringman JM, Simmons JH. Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology. 2000;55(6):870–1.PubMedCrossRef
68.
Zurück zum Zitat Di Giacopo R et al. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson’s disease. Mov Disord. 2012;27(4):559–61.PubMedCrossRef Di Giacopo R et al. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson’s disease. Mov Disord. 2012;27(4):559–61.PubMedCrossRef
69.
Zurück zum Zitat Brunetti V et al. Rivastigmine for refractory REM behavior disorder in mild cognitive impairment. Curr Alzheimer Res. 2014;11(3):267–73.PubMedCrossRef Brunetti V et al. Rivastigmine for refractory REM behavior disorder in mild cognitive impairment. Curr Alzheimer Res. 2014;11(3):267–73.PubMedCrossRef
70.
Zurück zum Zitat Carlander B, Touchon J, Ondze B, Billard M. REM sleep behavior disorder induced by cholinergic treatment in Alzheimer’s disease. J Sleep Res. 1996;5 suppl 1:28. Carlander B, Touchon J, Ondze B, Billard M. REM sleep behavior disorder induced by cholinergic treatment in Alzheimer’s disease. J Sleep Res. 1996;5 suppl 1:28.
71.
Zurück zum Zitat Shinno H et al. Successful treatment with Yi-Gan San for rapid eye movement sleep behavior disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(7):1749–51.PubMedCrossRef Shinno H et al. Successful treatment with Yi-Gan San for rapid eye movement sleep behavior disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(7):1749–51.PubMedCrossRef
72.
Zurück zum Zitat Shneerson JM. Successful treatment of REM sleep behavior disorder with sodium oxybate. Clin Neuropharmacol. 2009;32(3):158–9.PubMedCrossRef Shneerson JM. Successful treatment of REM sleep behavior disorder with sodium oxybate. Clin Neuropharmacol. 2009;32(3):158–9.PubMedCrossRef
73.•
Zurück zum Zitat Howell MJ et al. A novel therapy for REM sleep behavior disorder (RBD). J Clin Sleep Med. 2011;7(6):639–44A. This report in four medication refractory REM sleep behavior disorder patients showed evidence for decreased injury and symptoms, offering a novel approach to therapy without adverse effects.PubMedPubMedCentral Howell MJ et al. A novel therapy for REM sleep behavior disorder (RBD). J Clin Sleep Med. 2011;7(6):639–44A. This report in four medication refractory REM sleep behavior disorder patients showed evidence for decreased injury and symptoms, offering a novel approach to therapy without adverse effects.PubMedPubMedCentral
74.
Zurück zum Zitat Dumitrascu O et al. Parasomnia overlap disorder: a distinct pathophysiologic entity or a variant of rapid eye movement sleep behavior disorder? A case series. Sleep Med. 2013;14(11):1217–20.PubMedCrossRef Dumitrascu O et al. Parasomnia overlap disorder: a distinct pathophysiologic entity or a variant of rapid eye movement sleep behavior disorder? A case series. Sleep Med. 2013;14(11):1217–20.PubMedCrossRef
75.
Zurück zum Zitat Howell MJ, Schenck CH. Rapid eye movement sleep behavior disorder and neurodegenerative disease. JAMA Neurol. 2015;72(6):707–12.PubMedCrossRef Howell MJ, Schenck CH. Rapid eye movement sleep behavior disorder and neurodegenerative disease. JAMA Neurol. 2015;72(6):707–12.PubMedCrossRef
76.
Zurück zum Zitat Hurwitz TD et al. A retrospective outcome study and review of hypnosis as treatment of adults with sleepwalking and sleep terror. J Nerv Ment Dis. 1991;179(4):228–33.PubMedCrossRef Hurwitz TD et al. A retrospective outcome study and review of hypnosis as treatment of adults with sleepwalking and sleep terror. J Nerv Ment Dis. 1991;179(4):228–33.PubMedCrossRef
77.
Zurück zum Zitat Hauri PJ et al. The treatment of parasomnias with hypnosis: a 5-year follow-up study. J Clin Sleep Med. 2007;3(4):369–73.PubMedPubMedCentral Hauri PJ et al. The treatment of parasomnias with hypnosis: a 5-year follow-up study. J Clin Sleep Med. 2007;3(4):369–73.PubMedPubMedCentral
78.
Zurück zum Zitat Larsen V SD, Richardson J, Boeve BF, Silber MH, St. Louis EK. Clinical characteristics and treatment outcomes of patients treated with hypnosis for parasomnias. Sleep. 2016;39(Suppl (abstract)):A237. Larsen V SD, Richardson J, Boeve BF, Silber MH, St. Louis EK. Clinical characteristics and treatment outcomes of patients treated with hypnosis for parasomnias. Sleep. 2016;39(Suppl (abstract)):A237.
79.
Zurück zum Zitat Chagas MH et al. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series. J Clin Pharm Ther. 2014;39(5):564–6.PubMedCrossRef Chagas MH et al. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series. J Clin Pharm Ther. 2014;39(5):564–6.PubMedCrossRef
Metadaten
Titel
Treatment of REM Sleep Behavior Disorder
verfasst von
Youngsin Jung, MD, PhD
Erik K. St. Louis, MD
Publikationsdatum
01.11.2016
Verlag
Springer US
Erschienen in
Current Treatment Options in Neurology / Ausgabe 11/2016
Print ISSN: 1092-8480
Elektronische ISSN: 1534-3138
DOI
https://doi.org/10.1007/s11940-016-0433-2

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.